Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

HIV screening

This article was originally published in The Gray Sheet

Executive Summary

In a Sept. 9 1memo, CMS proposes to extend national coverage to lab-based immunoassay and rapid antibody assay screening for HIV in certain high-risk individuals, per U.S. Preventive Service Task Force guidelines. The agency opened its analysis for HIV screening on March 13, marking the first time CMS has initiated a national coverage determination for a screening tool since Congress granted it authority to add coverage for certain preventative services without the need for case-by-case congressional approval (2"The Gray Sheet" March 30, 2009). A final decision is expected by Dec. 8

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT027908

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel